Impact of Medication Adherence on Hospitalization Risk and Healthcare Cost

Dubois, 2000, Explaining drug spending trends: does perception match reality?, Health Aff (Millwood), 19, 231, 10.1377/hlthaff.19.2.231

1998, Medical Management of Type 2 Diabetes.

Balkrishnan, 1998, Outcomes and cost benefits associated with the introduction of inhaled corticosteroid therapy in a Medicaid population of asthmatic patients., Clin Ther, 20, 567, 10.1016/S0149-2918(98)80066-0

McCombs, 1990, The cost of antidepressant drug therapy failure: a study of antidepressant use patterns in a Medicaid population., J Clin Psychiatry, 51, 60

Gotto, 1999, Lowering LDL cholesterol: questions from recent meta-analyses and subset analyses of clinical trial data., Circulation, 99, E1, 10.1161/01.CIR.99.8.e1

Lichtenberg, 1996, Do (more and better) drugs keep people out of hospitals?, Am Econ Rev, 86, 384

Kleinke, 2001, The price of progress: prescription drugs in the health care market., Health Aff (Millwood), 20, 43, 10.1377/hlthaff.20.5.43

Nichol, 1999, A critical evaluation of the methodology of the literature on medication compliance., Ann Pharmacother, 33, 531, 10.1345/aph.18233

Schlenk, 2001, Compliance in Healthcare and Research., 57

Miller, 1997, Compliance with treatment regimens in chronic asymptomatic diseases., Am J Med, 102, 43, 10.1016/S0002-9343(97)00467-1

Groban, 1998, Clinical benefits and cost reduction associated with a comprehensive asthma management programme at a managed care organisation., Dis Manag Health Outcomes, 4, 93, 10.2165/00115677-199804020-00003

Thompson, 1998, Predictors of a medical-offset effect among patients receiving antidepressant therapy., Am J Psychiatry, 155, 824

McCulloch, 2000, Managing diabetes for improved health and economic outcomes., Am J Manag Care, 6, S1089

White, 2001, Impact of compliance on health care cost and utilization in patients with diabetes mellitus and cardiovascular disease Abstract., ASHP Midyear Clinical Meeting, 36, R

Rizzo, 1997, Variations in compliance among hypertensive patients by drug class: implications for health care costs., Clin Ther, 19, 1446, 10.1016/S0149-2918(97)80018-5

Balkrishnan, 2002, Self-reported health status, prophylactic medication use, and healthcare costs in older adults with asthma., J Am Geriatr Soc, 50, 924, 10.1046/j.1532-5415.2002.50221.x

Soumerai, 1987, Payment restrictions for prescription drugs under Medicaid: effects on therapy, cost, and equity., N Engl J Med, 317, 550, 10.1056/NEJM198708273170906

Soumerai, 1995, Computer-based drug-utilization review—risk, benefit, or boondoggle?, N Engl J Med, 332, 1641, 10.1056/NEJM199506153322411

Tamblyn, 2001, Adverse events associated with prescription drug cost-sharing among poor and elderly persons., JAMA, 285, 421, 10.1001/jama.285.4.421

Steinwachs, 2002, Pharmacy benefit plans and prescription drug spending., JAMA, 288, 1773, 10.1001/jama.288.14.1773

Stuart, 1999, Who bears the burden of Medicaid drug copayment policies?, Health Aff (Millwood), 18, 201, 10.1377/hlthaff.18.2.201

Heisler, 2004, The health effects of restricting prescription medication use because of cost., Med Care, 42, 626, 10.1097/01.mlr.0000129352.36733.cc

2003, International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM).

Deyo, 1992, Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases., J Clin Epidemiol, 45, 613, 10.1016/0895-4356(92)90133-8

Von Korff, 1992, A chronic disease score from automated pharmacy data., J Clin Epidemiol, 45, 197, 10.1016/0895-4356(92)90016-G

Clark, 1995, A chronic disease score with empirically derived weights., Med Care, 33, 783, 10.1097/00005650-199508000-00004

Cramer, 2004, A systematic review of adherence with medications for diabetes., Diabetes Care, 27, 1218, 10.2337/diacare.27.5.1218

Morris, 1997, Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependent diabetes mellitus., Lancet, 350, 1505, 10.1016/S0140-6736(97)06234-X

Tsuyuki, 2001, Poor adherence with hypolipidemic drugs: a lost opportunity., Pharmacotherapy, 21, 576, 10.1592/phco.21.6.576.34541

Olson, 2001, Cholesterol risk management: a systematic examination of the gap from evidence to practice., Pharmacotherapy, 21, 807, 10.1592/phco.21.9.807.34553

Avorn, 1998, Persistence of use of lipid-lowering medications: a cross-national study., JAMA, 279, 1458, 10.1001/jama.279.18.1458

1993, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus., N Engl J Med, 329, 977, 10.1056/NEJM199309303291401

1998, Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38)., BMJ, 317, 703, 10.1136/bmj.317.7160.703

Wagner, 2001, Effect of improved glycemic control on health care costs and utilization., JAMA, 285, 182, 10.1001/jama.285.2.182

Rubin, 1998, Clinical and economic impact of implementing a comprehensive diabetes management program in managed care., J Clin Endocrinol Metab, 83, 2635

1991, Effect of enalapril on survival in patients with reduced left-ventricular ejection fractions and congestive heart failure., N Engl J Med, 325, 293, 10.1056/NEJM199108013250501

1992, Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions., N Engl J Med, 327, 685, 10.1056/NEJM199209033271003

Graber, 1995, Hospitalization of patients with diabetes., Endocr Pract, 1, 399, 10.4158/EP.1.6.399